Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Sep;34(9):1637–1641. doi: 10.1128/aac.34.9.1637

In vitro selection of resistant Helicobacter pylori.

C E Haas 1, D E Nix 1, J J Schentag 1
PMCID: PMC171897  PMID: 2285275

Abstract

Four strains of Helicobacter pylori were subjected to an in vitro serial passage technique to compare the propensity of the organisms to develop resistance to seven classes of antibacterial agents. The passages were made on serially doubling concentrations of antibacterial agents incorporated into agar starting at one-half the base-line MIC. The frequency of spontaneous resistance was also determined for each strain at four and eight times the MIC of each antibacterial agent. Strains resistant to ciprofloxacin, metronidazole, erythromycin, and tobramycin were isolated. The experiments failed to select organisms resistant to bismuth subsalicylate, furazolidone, or amoxicillin, although the MIC of amoxicillin was increased 4- to 16-fold. With the exception of erythromycin, organisms with the selected resistance were stable after at least three passages on antibacterial agent-free medium. Spontaneous resistance rates were generally of a low magnitude and were not predictive of the serial passage results.

Full text

PDF
1637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chamberlain R. E. Chemotherapeutic properties of prominent nitrofurans. J Antimicrob Chemother. 1976 Dec;2(4):325–336. doi: 10.1093/jac/2.4.325. [DOI] [PubMed] [Google Scholar]
  2. Coghlan J. G., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E., Keane C., O'Morain C. Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet. 1987 Nov 14;2(8568):1109–1111. doi: 10.1016/s0140-6736(87)91545-5. [DOI] [PubMed] [Google Scholar]
  3. Dooley C. P., Cohen H. The clinical significance of Campylobacter pylori. Ann Intern Med. 1988 Jan;108(1):70–79. doi: 10.7326/0003-4819-108-1-70. [DOI] [PubMed] [Google Scholar]
  4. Glupczynski Y., Burette A., Labbe M., Deprez C., De Reuck M., Deltenre M. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol. 1988 Apr;83(4):365–372. [PubMed] [Google Scholar]
  5. Goodwin C. S., Marshall B. J., Blincow E. D., Wilson D. H., Blackbourn S., Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988 Feb;41(2):207–210. doi: 10.1136/jcp.41.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Graham D. Y. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):615–625. doi: 10.1016/s0016-5085(89)80057-5. [DOI] [PubMed] [Google Scholar]
  7. Graham D. Y., Klein P. D., Opekun A. R., Smith K. E., Polasani R. R., Evans D. J., Jr, Evans D. G., Alpert L. C., Michaletz P. A., Yoshimura H. H. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol. 1989 Mar;84(3):233–238. [PubMed] [Google Scholar]
  8. Hardy D. J., Hanson C. W., Hensey D. M., Beyer J. M., Fernandes P. B. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother. 1988 Nov;22(5):631–636. doi: 10.1093/jac/22.5.631. [DOI] [PubMed] [Google Scholar]
  9. Hirschl A. M., Hentschel E., Schütze K., Nemec H., Pötzi R., Gangl A., Weiss W., Pletschette M., Stanek G., Rotter M. L. The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer. Scand J Gastroenterol Suppl. 1988;142:76–81. doi: 10.3109/00365528809091718. [DOI] [PubMed] [Google Scholar]
  10. Lambert T., Mégraud F., Gerbaud G., Courvalin P. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother. 1986 Sep;30(3):510–511. doi: 10.1128/aac.30.3.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marshall B. J., Goodwin C. S., Warren J. R., Murray R., Blincow E. D., Blackbourn S. J., Phillips M., Waters T. E., Sanderson C. R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988 Dec 24;2(8626-8627):1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  12. McNulty C. A., Dent J. C., Ford G. A., Wilkinson S. P. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother. 1988 Nov;22(5):729–738. doi: 10.1093/jac/22.5.729. [DOI] [PubMed] [Google Scholar]
  13. McNulty C. A., Dent J. C. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):566–569. doi: 10.1007/BF01962617. [DOI] [PubMed] [Google Scholar]
  14. McNulty C. A., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):645–649. doi: 10.1136/bmj.293.6548.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mertens J. C., Dekker W., Ligtvoet E. E., Blok P. Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrob Agents Chemother. 1989 Feb;33(2):256–257. doi: 10.1128/aac.33.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Morgan D., Kraft W., Bender M., Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology. 1988 Nov;95(5):1178–1184. doi: 10.1016/0016-5085(88)90348-4. [DOI] [PubMed] [Google Scholar]
  17. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  18. Scully B. E. Metronidazole. Med Clin North Am. 1988 May;72(3):613–621. doi: 10.1016/s0025-7125(16)30761-1. [DOI] [PubMed] [Google Scholar]
  19. Simor A. E., Ferro S., Low D. E. Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori. Antimicrob Agents Chemother. 1989 Jan;33(1):108–109. doi: 10.1128/aac.33.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tenney J. H., Maack R. W., Chippendale G. R. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother. 1983 Jan;23(1):188–189. doi: 10.1128/aac.23.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES